healthcare laboratory News
-
Indutrade acquires UK Gas Technologies Group
UK Gas Technologies Ltd, which comprises Puretech Process Systems Ltd, Medical Gases Ltd and Microgas Systems Ltd, was acquired by Indutrade, an international industrial group that acquires and develops companies characterised by high-tech-know-how and an ability to build enduring, close relationships with customers and suppliers, on 17th September. The acquisition will enable UK based UK Gas ...
-
Fameco is featured in the press on Arab Health’s Daily Dose.
Currently, the Arab Health exhibition is being held in Dubai, one of the largest exhibitions for health professionals. Our Fameco Medical division is pleased to be there and to discover this morning that the Daily Dose magazine is talking about our activity and the eco-responsible stakes. ARAB HEALTH 2022: TOWARDS A MORE SUSTAINABLE FUTURE THROUGH REFURBISHING To promote its activities and meet ...
By Fameco
-
VIVAX BIO on a mission for COVID-19 drug discovery
Following its aspiring mission “Creating future opportunities” the biotechnological research laboratory “3D Bioprinting Solutions” and VIVAX BIO take an active part in pharmacological studies of various antiviral drugs. During the most difficult challenge in recent healthcare history cell biologists from the laboratory's research team began working with leading virologists ...
-
Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation `Phenotyping` (NGP) Platform for Positive Blood Culture and Sterile Body Fluid samples
Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced that its Next Generation 'Phenotyping' (NGP) platform has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for positive blood culture and sterile body fluid samples. "While currently under review ...
-
Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation ‘Phenotyping’ (NGP) Platform for Positive Blood Culture and Sterile Body Fluid Samples
Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced that its Next Generation 'Phenotyping' (NGP) platform has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for positive blood culture and sterile body fluid samples. "While currently under review ...
-
Selux Diagnostics Receives $9.6 Million in Additional Funding, Speeding Development of Breakthrough Rapid AST Platform
Selux Diagnostics, Inc., which is leading a new era in personalized medicine to treat superbug infections and combat antibiotic resistance, today announced that it has been awarded an additional $9.6 million from the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and ...
-
Selux Diagnostics Announces Appointment of John Wilson as Chief Commercial Officer
Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced that John Wilson has joined the company as Chief Commercial Officer. Wilson will lead the company's revenue growth for its rapid antimicrobial susceptibility testing (AST) technology as Selux prepares to commercialize its Next Generation ...
-
Selux Diagnostics Awarded $2.8 Million Grant from NIH for Commercialization of its NGP Platform
Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced that it has received a $2.8 million award from the U.S. National Institutes of Health (NIH) to help the company commercialize its Next Generation 'Phenotyping' (NGP) platform for rapid antimicrobial susceptibility testing (AST). Having ...
-
Selux Diagnostics Announces Selection of Three Abstracts for Poster Sessions at ASM Microbe 2019 Conference
Selux Diagnostics, Inc., which is leading a new era in personalized medicine to treat multidrug resistant organism infections and combat antibiotic resistance, today announced the selection of three Selux-crafted abstracts for poster sessions at the upcoming American Society for Microbiology, ASM Microbe 2019 scientific meeting on June 20-24 in San Francisco. "Selux Diagnostics is dedicated to ...
-
ILEX Medical to Invest 10 million NIS ($3.2 million)
NESS ZIONA, ISRAEL, November 29, 2021 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a cure for diabetes, announces a raise of 10 million NIS ($3.2 million) from ILEX Medical (TASE: ILX) one of the largest healthcare companies in Israel, in a private financing round. The raise was completed at a price of 4.26 NIS ($1.35) per share ...
-
Pacific Edge Results For Six Months Ended 30 September 2021
Pacific Edge is pleased to report continuing growth for the six months ended 30 September 2021 (1H22), with key performance metrics significantly ahead of the same time last year, driven by reimbursement milestones, increasing insurance coverage and adoption by urologists and healthcare organisations. Unaudited results for the six months ended 30 September 2021 (1H22) Summary of performance for ...
-
Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults
Highly sensitive Shield test offers convenient screening method that can be completed with simple blood draw, helping overcome barriers to compliance Test demonstrated sensitivity of 91% in colorectal cancer and 20% in advanced adenoma detection with specificity of 92% in validation studies PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology ...
-
Avelas Makes Senior Appointments and Provides Update on Pegloprastide Phase III Clinical Program
Ambareen Sheriff appointed as Vice President, Regulatory and Quality and Robin Stevens appointed as Non-Executive Director Novel, best-in-class agent for visualizing breast cancer margins to enter Phase III trial in 1H22 SAN DIEGO, CA – Avelas Biosciences, Inc. (“Avelas” or “the Company”), a clinical-stage drug-device company pioneering the field of fluorescence ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you